Lytix Biopharma grants 1,230,400 share options at NOK 9.26 under incentive plan

• Lytix Biopharma set a 1,230,400-share option grant under its long-term incentive program.
• Exercise price NOK 9.26 per share, set to the July 22 close on Euronext Growth Oslo.
• Most awards vest over four years; options expire five years from the grant date.
• Karim Benhadji received 384,500 options; 117,000 treated as vested at grant under a vesting schedule starting September 2025.
• Renée Amundsen received 769,000 options; 76,900 options went to a non-insider employee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.